Pharmacogenetics and Toxicology Publisher



Hasanzad M^{1, 2} ; Sarhangi N¹ ; Aghaei Meybodi HR³ ; Nikfar S^{1, 4}
Source: Encyclopedia of Toxicology# Fourth Edition: Volume 1-9 Published:2023

Abstract

Aim: The aim of the present review is to discuss the association of evidence-based pharmacogenomics (PGx) variants with some therapeutic information (mainly toxicity). Main concepts: Pharmacogenomics studies enable the recognition of variable therapeutic responses, the prediction of adverse drug reactions (ADRs) or toxicity, and the development and discovery of new drugs. Conclusion: There is sufficient scientific evidence to suggest that subgroups of patients with specific genetic variants or genetic variant-inferred phenotypes are likely to have altered drug metabolism and, in some cases, differential therapeutic effects, including differences in the risks of adverse events—such as drug toxicity according to the food and drug administration (FDA) pharmacogenetic associations. © 2024 Elsevier Inc. All rights reserved.